Keating Financial Advisory Services’s Crinetics Pharmaceuticals CRNX Stock Holding History

Keating Financial Advisory Services’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75	Sell	2 -3	-60%	-$112	﹤0.01%	2489
2026 Q1	$182	Buy	5 +1	+25%	+$45	﹤0.01%	2380
2025 Q4	$186	Buy	+4	New	+$178	﹤0.01%	2081

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's CRNX Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Crinetics Pharmaceuticals (CRNX) stake by 60% in Q2 2026, selling an estimated $112 and leaving 2 shares worth $75. The position accounts for ﹤0.01% of the portfolio, ranked #2489.

Keating Financial Advisory Services first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $186 in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Keating Financial Advisory Services held 2 shares of Crinetics Pharmaceuticals worth $75 as of Q2 2026.
Keating Financial Advisory Services sold 3 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $112.
Crinetics Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2489 holding.
Keating Financial Advisory Services first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
Keating Financial Advisory Services's Crinetics Pharmaceuticals position peaked at $186 in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.